[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [ACTIVE] · [HEALTH]

16 clusters · 59 sources · 61 days · First seen · Last updated

Clinical applications and access of CAR-T cell therapy

Overview

CAR-T cell therapy continues to expand its clinical utility across oncology and autoimmune diseases. In oncology, the therapy is transforming treatment for aggressive lymphomas and resistant blood cancers. A significant milestone was highlighted in the CARE study, where a three-year-old boy achieved complete remission from metastatic hepatoblastoma using T cells modified to target the Glypican-3 (GPC3) protein. Recent data regarding Johnson & Johnson’s cilta-cel has demonstrated long-term efficacy in treating multiple myeloma, with 50 percent of patients in a phase 2 study remaining alive without disease progression for at least five years.

Research is now broadening to include more diverse patient populations and specific malignancies. Oncology specialists are evaluating CAR T-cell therapy and targeted agents for chronic lymphocytic leukemia (CLL). Furthermore, investigations by the AIDS Malignancy Consortium and the Center for International Blood and Marrow Transplant Research are examining the safety of CAR T-cell therapy and bispecific antibodies in patients with HIV-associated aggressive B-cell non-Hodgkin lymphoma. Preliminary matched cohort analysis suggests that cytokine release syndrome may occur less frequently in HIV-positive patients receiving CD19-directed CAR T-cell therapy compared to those without HIV.

Clinical access is also expanding geographically and therapeutically. In Mexico, Cofepris has authorized the CARLLA-B1 protocol, the first domestic clinical trial to evaluate MB-CART19 therapy for adults with relapsed or refractory acute lymphoblastic leukemia. Additionally, researchers at the Yale School of Medicine are exploring the use of CAR-T as a ‘living drug’ to target the underlying causes of severe autoimmune conditions, such as lupus, multiple sclerosis, and scleroderma.

Entities

New England Journal of Medicine · Baylor College of Medicine · Johnson & Johnson · Nature Medicine · Mayo Clinic

Timeline

  1. [HEALTH] 2 sources
    Oncology researchers expand immunotherapy research for CLL and HIV-associated lymphoma

    Oncology researchers are expanding the use of CAR T-cell therapies and bispecific antibodies for relapsed CLL and HIV-associated lymphomas, addressing gaps in previous clinical trial populations.

  2. [HEALTH] 5 sources
    CAR-T cell therapy expands into leukemia trials and autoimmune research

    CAR-T cell therapy is advancing through new clinical trials in Mexico for leukemia and research at Yale for autoimmune diseases like lupus.

  3. [HEALTH] 8 sources
    CAR T cell therapy shows long-term myeloma remission and specific risks

    New data shows 50% of multiple myeloma patients achieved five-year remission with cilta-cel CAR T therapy, while studies also identify persistent intestinal inflammation as a key clinical complication.

  4. [HEALTH] 2 sources
    CAR T-cell therapy linked to severe inflammatory complications

    Medical research has identified biological drivers of severe inflammatory complications in CAR T-cell therapy, including intestinal enterocolitis and fatal hyperinflammation syndromes.

  5. [HEALTH] 2 sources
    Researchers develop new strategies to enhance CAR T-cell cancer therapies

    Researchers at the Mayo Clinic and City of Hope are developing new CAR T-cell technologies to combat tumor evolution and antigen loss, allowing for more adaptive and effective cancer immunotherapy.

  6. [HEALTH] 5 sources
    Experimental CAR T-cell therapy treats severe pediatric liver cancer

    A three-year-old in the US has overcome hepatoblastoma, a rare liver cancer, using experimental CAR T-cell immunotherapy, marking a potential breakthrough for treating solid tumors.

  7. [HEALTH] 3 sources
    CAR-T cell therapy shows potential for multiple sclerosis and thyroid cancer

    New research explores expanding CAR-T cell therapy, showing promise for treating multiple sclerosis symptoms via in vivo reprogramming and improving solid tumor targeting in thyroid cancer.

  8. [HEALTH] 3 sources
    Experimental CAR T-cell therapy induces remission in child with liver cancer

    A 3-year-old boy has achieved long-term remission from advanced liver cancer through an experimental CAR T-cell therapy targeting the glypican-3 protein.

  9. [HEALTH] 7 sources
    CAR-T cell therapy shows promise in treating refractory rheumatoid arthritis

    A pilot clinical trial at Charité Berlin shows that CAR-T cell therapy can successfully reduce inflammation and induce remission in patients with severe, treatment-resistant rheumatoid arthritis.

  10. [HEALTH] 6 sources
    Experimental CAR T therapy induces remission in child with metastatic liver cancer

    A 3-year-old boy with metastatic hepatoblastoma has achieved complete remission after two doses of experimental GPC3-targeted CAR T cell therapy, according to a study in The New England Journal of Medicine.

  11. [HEALTH] 6 sources
    German Rheumatology Congress explores new immunotherapies

    At the German Rheumatology Congress, experts discussed using CAR-T cell immunotherapy to treat severe autoimmune diseases and the evolving role of surgery in managing rheumatic conditions.

  12. [HEALTH] 3 sources
    CAR-T cell therapy advances in cancer treatment and insurance coverage

    CAR-T cell therapy is advancing as a critical immunotherapy for blood cancers. Experts in Taiwan urge expanding insurance coverage to second-line treatment and leveraging CDMO capabilities to access next-gen T-

  13. [HEALTH] 5 sources
    CAR-T cell therapy shows promise in treating autoimmune diseases

    New clinical trials suggest CAR-T cell therapy may offer remission for autoimmune diseases like multiple sclerosis and rheumatoid arthritis by targeting harmful B-cells.

  14. [HEALTH] 2 sources
    Charité Berlin reports rheumatoid arthritis remission using CAR-T therapy

    A phase-1 study by Charité Berlin shows that CAR-T cell therapy can induce remission in patients with severe, treatment-resistant rheumatoid arthritis.

  15. [HEALTH] 2 sources
    CAR-T cell therapy advances treatment for aggressive lymphomas

    CAR-T cell immunotherapy is providing new hope for patients with refractory or relapsed aggressive lymphomas, such as DLBCL, by reprogramming immune cells to fight cancer.

  16. [HEALTH] 2 sources
    CAR-T Cell Therapy Enables Safe Pregnancy for Women with Autoimmune Diseases

    A study published in NEJM shows CD19‑CAR‑T therapy enables women with autoimmune diseases to have safe, uncomplicated pregnancies and healthy babies, with no disease relapse and no need for immunosuppressants.

Sources

actualidad.rt.com · ad-hoc-news.de · aend.de · aerztliches-journal.de · anlatilaninotesi.com.tr · baoquangtri.vn · cancernetwork.com · ciencias.uy · codirp.it · denesen.mk · diariodelsur.com.co · doctorulzilei.ro · drug-dev.com · emjreviews.com · excelsior.com.mx · fanpage.it · farmaciavirtuale.it · fnob.it · gizmodo.com · gzt.com · hvg.hu · ilfattonisseno.it · immedicohospitalario.es · isanidad.com · jovempan.uol.com.br · kibrisgercek.com · kreiszeitung.de · lamilano.it · laprensa.mx · latercera.com · lecodellitorale.it · leinetal24.de · mantovauno.it · mediapress24.it · medicaldialogues.in · nachrichten-kl.de · news-medical.net · news.yam.md · newswise.com · ojornaldaregiao.com.br · oncnursingnews.com · ool.de · ortho-online.de · peoplenews.tw · perfil.com · periodicodaily.com · prv.mk · senzalinea.it

This summary has been updated 14 times: see revision history